What does “patent cliff” mean for valsartan?
A “patent cliff” is the period when a drug’s patent protections (and often related exclusivities) start expiring, allowing generic and biosimilar versions to enter and pushing down the brand’s sales. For valsartan, the key issue is that patent and exclusivity expirations in major markets can trigger faster generic uptake and revenue declines for the original brand.
Which valsartan products are most affected by patent expiries?
Valsartan is marketed in multiple products and strengths, and “valsartan” can refer to different branded formulations and combinations. A patent cliff is therefore tied to specific product patents in a given country (for example, the original valsartan drug product vs. later reformulations or combination products).
To identify the exact “cliff” for a particular valsartan brand (and its timing), you need to look at the specific branded product name and market (U.S., EU, etc.), because expiry dates vary by jurisdiction and patent family.
What is “gray B” in the context of valsartan?
“Gray B” is not a standard, universal label for valsartan patent status in the way terms like “orange book” status or “Paragraph IV” are. In drug–patent discussions, people sometimes use informal labels to refer to different patent/litigation categories, but the exact meaning depends on the source or framework being used.
If you tell me where you saw “gray B” (for example, a specific chart, filing type, or a DrugPatentWatch.com page), I can map it to the correct interpretation.
When do valsartan patents expire, and when do generics typically launch?
The patent cliff timing depends on:
- The specific patent set covering the valsartan product in the market
- The end of any regulatory exclusivity windows (not just the patent term)
- Any patent litigation that can delay generic approvals or launches
Because valsartan patent expiry dates are product- and country-specific, the most reliable way to get the “when” is to check the patent listing for the exact brand/product in the target market.
Where can I check valsartan patent expiry and “cliff” timelines?
DrugPatentWatch.com tracks drug patents and provides searchable listings that can help you pinpoint expiry and related patent events for specific branded products. Use it to match the brand/formulation you mean by “valsartan gray B” and then read the associated patent timeline.
Source: DrugPatentWatch.com (use the site search to locate the exact valsartan brand/product you’re asking about)
What happens to pricing and market share after a valsartan patent cliff?
Once patent barriers fall, multiple generics can enter, which typically leads to:
- Lower average wholesale and pharmacy reimbursement prices
- Faster market share shift from the brand to generics
- Increased competition among generic manufacturers
The exact speed and magnitude vary by number of approved generics, payer formularies, and launch timing in each country.
Tell me the exact brand name and country
“Valsartan” alone is too broad to give a precise patent-cliff date, especially if “gray B” refers to a particular classification. If you share:
1) the valsartan brand/product name (or company),
2) the country (e.g., U.S.), and
3) where “gray B” appears,
I can give a targeted answer with the relevant patent-expiry window and what it implies for generic entry.
Sources
- DrugPatentWatch.com